Previous located in Delaware, Modulation Therapeutics is structured around early stage first in class molecules targeting the tumor microenvironment. Typically, tumors that home/metastasize to the bone are difficult to treat with standard chemotherapy. Anchored in technology licensed from the Moffitt Cancer Center in Tampa and based on a premise that to eradicate tumors that home or metastasize to the bone marrow compartment must include disrupting tumor-host interactions, the company is developing a novel first in class peptide mimetic drug called MT-101 for multiple myeloma and other cancers that metastasize to bone. The novel mechanism of action that is MT-101 differentiates from all other existing drugs for myeloma. Preclinical data show promising single agent and combination (Velcade) efficacy with no overt toxicity in vivo. In part fundingby the e Multiple Myeloma Research Foundation, Modulation's effort is to develop the lead compound for the treatment of Multiple Myeloma, a plasma cell tumor which homes to the bone and a disease which currently has no curative therapies available. Lead Compounds are MTI-101, MTI-201 and MTI-301 with IND filing (MTI-101) during first quarter 2018
